Weida Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weida Huang has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Zhikang Qian
Department of Biochemistry, School of Life Sciences, Fudan University, 220 Handan Road, Shanghai 200433, China
5 shared publicationsChang Tan
Department of Biochemistry, School of Life Science, Fudan University, 220 Handan Road, Shanghai 200433, China
4 shared publicationsJie Hong
Department of Biochemistry, School of Life Sciences, Fudan University, 220 Handan Road, Shanghai 200433, China
4 shared publicationsShuiyuan Shen
Department of Biochemistry, School of Life Sciences, Fudan University, Shanghai 200433, China
4 shared publicationsBaoqin Xuan
Department of Biochemistry, School of Life Sciences, Fudan University, 220 Handan Road, Shanghai 200433, China
3 shared publicationsHonghai Zhang
Department of Biochemistry, School of Life Sciences, Fudan University, 200433 Shanghai, PR China
3 shared publications
Latest Publications
- 17 September 2013
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 72 (5) , 1031-1041
DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft
Purpose Capecitabine is one of the few chemotherapy drugs with high oral availability. Recently, sodium dichloroacetate (DCA) has shown great potential as an anticancer agent. In the present study, we assessed the anticancer effect of DCA in combination with capecitabine for cancers that modestly expressed TP. Methods A mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft were used to assess the effect of DCA and capecitabine combined treatment. Histology and immunohistochemistry were used to detect the apoptosis and proliferation of cancer cells. Real-time PCR and Western blot were carried out to detect the expression of TP and caspases, respectively. Results For the first time, we report that DCA increased the antitumor effects of capecitabine in a mouse B16 allograft and a human A549 xenograft by promoting apoptosis of tumor cells. DCA has little effect on the expression of TP. Conclusions Our finding suggests that DCA in combination with capecitabine might be potential as a new therapeutic regimen against some cancers.
- 17 September 2013
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 72 (5) , 1031-1041
DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft
Purpose Capecitabine is one of the few chemotherapy drugs with high oral availability. Recently, sodium dichloroacetate (DCA) has shown great potential as an anticancer agent. In the present study, we assessed the anticancer effect of DCA in combination with capecitabine for cancers that modestly expressed TP. Methods A mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft were used to assess the effect of DCA and capecitabine combined treatment. Histology and immunohistochemistry were used to detect the apoptosis and proliferation of cancer cells. Real-time PCR and Western blot were carried out to detect the expression of TP and caspases, respectively. Results For the first time, we report that DCA increased the antitumor effects of capecitabine in a mouse B16 allograft and a human A549 xenograft by promoting apoptosis of tumor cells. DCA has little effect on the expression of TP. Conclusions Our finding suggests that DCA in combination with capecitabine might be potential as a new therapeutic regimen against some cancers.
- Open Access
- 1 February 2012
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 7, 827-34
Ferritin light chain and squamous cell carcinoma antigen 1 are coreceptors for cellular attachment and entry of hepatitis B virus
Peer reviewed article authored by (Hao ZJ, Zheng L, Kluwe L, Huang WD). Read article or submit your manuscript for publishing.
- 1 February 2012
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 7, 827-34
Open AccessFerritin light chain and squamous cell carcinoma antigen 1 are coreceptors for cellular attachment and entry of hepatitis B virus
Peer reviewed article authored by (Hao ZJ, Zheng L, Kluwe L, Huang WD). Read article or submit your manuscript for publishing.
- Open Access
- 19 October 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (10) , e26466
High-Dose siRNAs Upregulate Mouse Eri-1 at both Transcription and Posttranscription Levels
The eri-1 gene encodes a 3′ exonuclease that can negatively regulate RNA interference via siRNase activity. High-dose siRNAs (hd-siRNAs) can enhance Eri-1 expression, which in return degrade siRNAs and greatly reduces RNAi efficiency. Here we report that hd-siRNAs induce mouse Eri-1 (meri-1) expression through the recruitment of Sp1, Ets-1, and STAT3 to the meri-1 promoter and the formation of an Sp1-Ets-1-STAT3 complex. In addition, hd-siRNAs also abolish the 3′ untranslated region (UTR) mediated posttranscriptional repression of meri-1. Our findings demonstrate the molecular mechanism underlying the upregulation of meri-1 by hd-siRNA.
- 19 October 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (10) , e26466
Open AccessHigh-Dose siRNAs Upregulate Mouse Eri-1 at both Transcription and Posttranscription Levels
The eri-1 gene encodes a 3′ exonuclease that can negatively regulate RNA interference via siRNase activity. High-dose siRNAs (hd-siRNAs) can enhance Eri-1 expression, which in return degrade siRNAs and greatly reduces RNAi efficiency. Here we report that hd-siRNAs induce mouse Eri-1 (meri-1) expression through the recruitment of Sp1, Ets-1, and STAT3 to the meri-1 promoter and the formation of an Sp1-Ets-1-STAT3 complex. In addition, hd-siRNAs also abolish the 3′ untranslated region (UTR) mediated posttranscriptional repression of meri-1. Our findings demonstrate the molecular mechanism underlying the upregulation of meri-1 by hd-siRNA.
- 30 November 2009
- Published by Elsevier in Virus Research
- Vol. 145 (2) , 307-311
Involvement of mitochondrial permeability transition in hepatitis B virus replication
- 30 November 2009
- Published by Elsevier in Virus Research
- Vol. 145 (2) , 307-311
Involvement of mitochondrial permeability transition in hepatitis B virus replication
- 1 October 2007
- Vol. 25 (5) , 397-400
[Preparation and identification of immune serum against recombinant fusion protein of rhoptry 2 and major surface protein 1 from Toxoplasma gondii].
To prepare and identify immune serum against the recombinant fusion protein of rhoptry 2 (ROP2) and major surface protein 1(P30) from Toxoplasma gondii. The constructed recombinant plasmid of pET28b/ROP2-P30 was transformed to a bacterium BL21-Codon Plus (DE3)-RIL strain and was expressed under IPTG induction. Cells were lysed by multiple rounds of sonication to obtain supernatant and inclusion body respectively. The inclusion body was washed with 2 mol/L and 4 mol/L urea to remove the nonspecific protein. The washed products dissolved in 8 mol/L urea were received by SDS-PAGE. Two rabbits were immunized with the fusion protein rROP2-P30 and sera from the rabbits were collected. Immune diffusion test, indirect ELISA and Western-blot were used to detect antibody titer and specificity of the immune serum against rROP2-P30. Immune diffusion test demonstrated that specific immune serum were obtained. Indirect ELISA confirmed that the antibody titer in the serum reached 1:12 800 and the rROP2-P30 was recognized by specific IgG in this serum by Western-blot analysis. Specific immune serum against the recombinant fusion protein rROP2-P30 has been prepared.
- 1 October 2007
- Vol. 25 (5) , 397-400
[Preparation and identification of immune serum against recombinant fusion protein of rhoptry 2 and major surface protein 1 from Toxoplasma gondii].
To prepare and identify immune serum against the recombinant fusion protein of rhoptry 2 (ROP2) and major surface protein 1(P30) from Toxoplasma gondii. The constructed recombinant plasmid of pET28b/ROP2-P30 was transformed to a bacterium BL21-Codon Plus (DE3)-RIL strain and was expressed under IPTG induction. Cells were lysed by multiple rounds of sonication to obtain supernatant and inclusion body respectively. The inclusion body was washed with 2 mol/L and 4 mol/L urea to remove the nonspecific protein. The washed products dissolved in 8 mol/L urea were received by SDS-PAGE. Two rabbits were immunized with the fusion protein rROP2-P30 and sera from the rabbits were collected. Immune diffusion test, indirect ELISA and Western-blot were used to detect antibody titer and specificity of the immune serum against rROP2-P30. Immune diffusion test demonstrated that specific immune serum were obtained. Indirect ELISA confirmed that the antibody titer in the serum reached 1:12 800 and the rROP2-P30 was recognized by specific IgG in this serum by Western-blot analysis. Specific immune serum against the recombinant fusion protein rROP2-P30 has been prepared.
- 1 August 2007
- Vol. 29 (8) , 566-9
[Effect of EPHA2-siRNA plasmid on biological behavior of human osteosarcoma cells in vitro].
To investigate the role of EPHA2 in regulating apoptosis, proliferation and vasculogenic mimicry of osteosarcoma cells, by gene silencing through RNA interference. EPHA2-siRNA plasmids were achieved by gene cloning. The plasmids were transfected into human osteosarcoma cells (MG63). The expression level of EPHA2 protein was measured by Western blotting. The proliferation, apoptosis and vasculogenic mimicry features of osteosarcoma MG63cells were assessed by light microscopy, MTIP assay, flow cytometry, annexin V-FITC/PI and HE staining, respectively. The EPHA2-siRNA plasmid was confirmed by DNA sequencing. After treatment with Sequence-specific siRNA targeted EPHA2, the protein level of the transfected group decreased significantly. As compared to non-siRNA transfected cells, the transfected group showed lower proliferation, higher and earlier apoptosis and less osteosarcoma-generated vasculogenic mimicry. EPHA2 gene may be involoved in apoptosis and proliferation of osteosarcoma cells, and may be necessary for vasculogenic mimicry. Down-regulation of EPHA2 expression by sequence-specific siRNA may be considered as a new option in the treatment of EPHA2 over-expressing cancer including osteosarcoma in future.
- 1 August 2007
- Vol. 29 (8) , 566-9
[Effect of EPHA2-siRNA plasmid on biological behavior of human osteosarcoma cells in vitro].
To investigate the role of EPHA2 in regulating apoptosis, proliferation and vasculogenic mimicry of osteosarcoma cells, by gene silencing through RNA interference. EPHA2-siRNA plasmids were achieved by gene cloning. The plasmids were transfected into human osteosarcoma cells (MG63). The expression level of EPHA2 protein was measured by Western blotting. The proliferation, apoptosis and vasculogenic mimicry features of osteosarcoma MG63cells were assessed by light microscopy, MTIP assay, flow cytometry, annexin V-FITC/PI and HE staining, respectively. The EPHA2-siRNA plasmid was confirmed by DNA sequencing. After treatment with Sequence-specific siRNA targeted EPHA2, the protein level of the transfected group decreased significantly. As compared to non-siRNA transfected cells, the transfected group showed lower proliferation, higher and earlier apoptosis and less osteosarcoma-generated vasculogenic mimicry. EPHA2 gene may be involoved in apoptosis and proliferation of osteosarcoma cells, and may be necessary for vasculogenic mimicry. Down-regulation of EPHA2 expression by sequence-specific siRNA may be considered as a new option in the treatment of EPHA2 over-expressing cancer including osteosarcoma in future.
- 30 June 2007
- Published by Elsevier in Virus Research
- Vol. 126 (1-2) , 172-178
RNA interference against hepatitis B virus with endoribonuclease-prepared siRNA despite of the target sequence variations
- 30 June 2007
- Published by Elsevier in Virus Research
- Vol. 126 (1-2) , 172-178
RNA interference against hepatitis B virus with endoribonuclease-prepared siRNA despite of the target sequence variations
- 20 December 2006
- Published by China Science Publishing & Media Ltd. in Acta Polymerica Sinica
- Vol. 6 (9) , 1078-1082
A MEMBRANE PROTEIN/POLYMER COMPOSITE FILM WITH PHOTOCHROMIC RESPONSE
- 20 December 2006
- Published by China Science Publishing & Media Ltd. in Acta Polymerica Sinica
- Vol. 6 (9) , 1078-1082
A MEMBRANE PROTEIN/POLYMER COMPOSITE FILM WITH PHOTOCHROMIC RESPONSE
- 30 June 2006
- Published by Elsevier in Virus Research
- Vol. 118 (1-2) , 150-155
EsiRNAs inhibit Hepatitis B virus replication in mice model more efficiently than synthesized siRNAs
- 30 June 2006
- Published by Elsevier in Virus Research
- Vol. 118 (1-2) , 150-155
EsiRNAs inhibit Hepatitis B virus replication in mice model more efficiently than synthesized siRNAs
- 15 June 2006
- Published by Elsevier in Immunology Letters
- Vol. 105 (2) , 167-173
Fusion protein of ATPase domain of Hsc70 with TRP2 acting as a tumor vaccine against B16 melanoma
- 15 June 2006
- Published by Elsevier in Immunology Letters
- Vol. 105 (2) , 167-173
Fusion protein of ATPase domain of Hsc70 with TRP2 acting as a tumor vaccine against B16 melanoma